Children with high risk malignancies are usually given permanent (Hickman-type) tunneled silicone rubber central venous catheters (silicone CVCs) for the administration of chemotherapy. In the past, these children received an additional short-term polyurethane dialysis CVC for stem cell apheresis. To avoid placement of an additional short-term CVC, we started in 1995 to use pre-existing silicone CVCs for PBPC harvests. From May 1996 to February 1999 we evaluated 165 harvests in 37 children and 14 young adults (16-28 years) treated with high-dose chemotherapy and stem cell support, comparing CD34
Stem cell apheresis has become a routine procedure in adults and also children with high risk malignancies. 1, 2 Harvest procedures in pediatric patients are complicated by low patient body mass, associated with metabolic and hemodynamic instability, small veins, citrate toxicity, and patient compliance. [1] [2] [3] [4] Most problems, such as reduced harvest efficiency and tolerability have been improved by adaptations of the cell separator and by reduction of extracorporal volume. [5] [6] [7] [8] However, the management of safe vascular access, allowing a sustained adequate flow ratio over an extended time frame on repeated occasions, remains a serious practical problem.
Non-tunneled polyurethane CVCs for continuous blood flow are often used in adults, 9 but insertion may cause local vessel damage because of the stiffness of the material, with subsequent local thrombosis and infectious complications. 8, 10 Children with high risk malignancies primarily receive silicone CVCs at the initiation of chemotherapy, leaving their peripheral veins in good condition. These CVCs are adapted to the patient's size by shortening the distal tip during insertion. For PBPC apheresis, one lumen can be used as a draw line but to prevent a short circuit between the large and the small lumens an additional peripheral venous cannula must be inserted as a return line. Alternatively, placing an additional polyurethane dialysis CVC for PBPC collection requires anesthesia and involves insertion and removal risks, whereas using an additional peripheral cannula for the duration of the harvest is more easily accepted by the children and their parents.
However, a high incidence of occlusions in silicone CVCs, have been reported especially after GM-CSF administration, [10] [11] [12] [13] and wall collapse may complicate the procedure when it is performed using softer catheter materials. To reduce the risk of occlusion, different anticoagulation regimens including oral acetylsalicylic acid, heparin flushing or continuous heparin infusion have been described. 11, 13 The aim of this study was to assess whether pre-existing silicone CVCs are suitable for PBPC harvesting in children and young adults. In pediatric and young adult patients, 79% of stem cell harvests could be performed using preexisting central tunneled silicone CVCs and peripheral venous cannulae as the draw line (or return line), without significant reduction of harvest efficiency or tolerability. Age and size specific differences were observed, but no significant reduction of CD34 + harvest efficiency was found. 
Patients and methods
Thirty males and 21 females were treated and underwent PBPC collection according to protocols of the German/Austrian Society of Pediatric Oncology and Hematology, from May 1996 to February 1999. Diagnoses were disseminated or relapsed Ewing's sarcoma in 12 patients (four of them were relapsed), central primitive neuroectodermal tumor in six cases, meduloblastoma in six cases, disseminated alveolar rhabdomyosarcoma in six patients (one was a relapse), disseminated neuroblastoma in five cases, metastatic osteosarcoma in four patients (three were relapses), lymphoma in three patients, acute leukemia in two patients, disseminated nephroblastoma in two patients, rhabdoid tumor in two patients and seminoma, anaplastic ependymoma, and pleuropulmonary blastoma in one case each (Table 1) . Ages ranged from 8 months to 28 years and body weight from 9 to 92 kg. Patients' characteristics are shown in Table 2 . Informed consent for the apheresis procedures was obtained from all parents and/or patients.
Venous access
In all patients a primary attempt was made to use pre-existing CVCs for PBPC collection. At our institution, CVC placement is restricted to a small group of experienced pediatricians. In patients with high risk malignancies, a tunneled silicone rubber double lumen (Hickman-type) CVC (BARD Davol, Salt Lake City, UT, USA) is routinely inserted at the beginning of chemotherapy. In the event of inadequate function of pre-existing silicone CVCs or in patients without pre-existing CVCs, a member of the pediatric apheresis team evaluated the feasibility of access through peripheral veins before starting PBPC mobilization. In silicone CVCs, the large lumen was primarily used as a draw line and a large peripheral venous cannula was established as the return line. The small lumen was never used as a return line to prevent short-circuiting between the draw and return lines. When repeated flow reductions occurred (in seven silicone CVCs), the draw lines were changed to the small CVC lumen or to a peripheral venous cannula. Three groups were established depending on which venous access was used as a draw line: (1) 105 apheresis procedures used a 7-12 French double lumen silicone CVC; (2) 35 procedures used double lumen tunneled Permkath (Quinton Instr., Seattle, WA, USA) or a double lumen Arrow (8 and 12 French, Arrow, Reading, PA, USA) polyurethane CVC; (3) 25 procedures use a variety of sizes (1.0-2.0 mm; 20-14 G) of peripheral venous cannulae (cf. Table 3 , which also lists return lines).
Routine care of CVC included sterile handling, daily change of connectors when in use, catheter flushing with 50 IU low molecular weight heparin/ml 0.9% sodium chloride when used more than twice during 24 h, and with 200 IU of low molecular weight heparin/ml 0.9% sodium chloride after disuse for longer than 24 h, but at least every 4th day. When one lumen of a CVC had been used as the draw line and repeated flow reductions had necessitated a change in access, the lumen was flushed with 50 IU low molecular weight heparin/ml 0.9% sodium chloride according to the regimen described above.
Mobilization regimen
PBPC were mobilized by chemotherapy according to standard treatment protocols, followed by G-CSF 10 g/kg (Neupogen, Amgen, Vienna, Austria) once daily in 45 mobilization procedures, by G-CSF 10 g/kg once daily plus erythropoietin (Erypo, Jansen-Cilag, Vienna, Austria) 100 IU/kg daily in 10 and by G-CSF 10 g/kg once daily plus erythropoietin 100 IU/kg 3 × week in nine cases. Three mobilization procedures were performed with G-CSF 10 g/kg/day and GM-CSF (Leukomax, Novartis, Vienna, Austria) 10 g/kg/day.
Stem cell harvest
Cells were collected using a Fenwal CS 3000 Plus Omnix (Baxter, Deerfield, IL, USA) continuous flow blood cell separator with special PBPC programs adapted to the patient's weight. The procedures were performed in an intermediate care setting by a member of the pediatric apheresis team experienced in pediatric intensive care. For children weighing less than 20 kg (50 apheresis procedures), the extracorporal line was primed with irradiated, leukocyte-depleted packed red blood cells, and the hematocrit was adjusted by adding 5% human albumin. Among patients of 20-30 kg body weight (14 apheresis procedures) the extracorporal line was primed with 0.9% sodium chloride mixed with human albumin to produce an albumin content of 4% (200 ml 20% human albumin + 800 ml 0.9% sodium chloride). Patients above 30 kg (100 apheresis procedures) were primed with the closed system apheresis kit (Baxter). Fluid balance was maintained by Ringer's solution to which 0.6% calcium gluconate was added to reduce citrate toxicity (60 ml 10% calcium gluconate/1000 ml Ringer's solution). The infusion was given through the return line and adjusted for patient weight to maintain the appropriate pediatric fluid balance. Independent of mobilization regimen, PBPC collections were preferably started when the CD34 + concentration was greater than 20 cells/l of peripheral blood. Only in poor mobilizers was the apheresis procedure started at lower levels. CD34
+ cells/l peripheral blood ranged between 2 and 700 (mean 86) before the start of apheresis. In most patients, the equivalent of three times the body blood volume was processed. Blood flow rates ranged between 10 and 65 (mean 43) ml/min. In 165 collection procedures a mean blood volume of 7666 ml (range 1800-19 600) was processed, corresponding to a mean relative blood volume of 206 (range 77-308) ml/kg body weight. Acid-citratedextrose solution was used at a mean ratio of 1:11 (range Bone Marrow Transplantation 1:9-1:13) and supplied to the proximal draw line to prevent coagulation. Average collection duration was 3 h 20 min (range 00:42-05:44 h) and the mean number of apheresis procedures performed per patient was two (range 1-4) after each PBPC mobilization (Table 4 ). Children were accompanied by a parent, who was asked to distract the child's attention to reduce anxiety, and to bring videos and tapes of their choice. Only one patient, a 1.-year-old girl weighing 9 kg, needed sedation with 5 mg/kg phenobarbital (Nembutal; Richter Pharma, Wels, Austria) during two collections.
Analysis of CD34 collection efficiency
We determined the CD34 + cell collection efficiency of each harvest according to the formula: leukocytes in the harvest × CD34 cells in the harvest × harvest volume/(CD34 cells before + CD34 cells after harvest/2) × processed blood volume during harvest.
CD34 analysis
PBPC specimens (1 ml) were prepared for flow cytometric analysis as described previously.
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Statistical analysis
Statistical analyses were performed using the KruskalWallis analysis of variance.
Results
Venous access
There were no complications during CVC placement in our 51 patients. One infection (0.6%) in a silicone CVC was directly associated with stem cell apheresis. Treatment with local and systemic antibiotics was sufficient and the catheter did not have to be removed. In the silicone CVC group, using the large lumen as draw line, we experienced seven cases (6.7%) of blood flow reduction, indicating partial occlusion, but did not observe any incidence of total occlusion. No treatment other than routine flushing after apheresis was necessary. In the polyurethane CVC group, an 8 French double lumen catheter occluded during one apheresis (2.9%), and the draw line had to be changed to a peripheral venous cannula. In the peripheral venous cannula group, blood flow decrease was observed in six of 25 collections (24%). When used as the return line, the small lumen of a double lumen 9 French silicone CVC occluded during two collections, and three times a decreased return flow indicated partial occlusion of peripheral venous cannulae (Table 3) .
Harvest
CD34
+ cell results for a single collection ranged from between 0.15 and 87 × 10 6 /kg with a mean of 6.53 × 10 6 /kg (Table 4) . Harvest efficiency was calculated with the formula described in the Material and methods section, which included processed blood volume. The overall efficiency of CD34 + cell collections was 59% (range 11.4-129.9), in group 1 with silicone CVCs, 58.9% (11.4-117.4), in group 2 with polyurethane CVCs, 56.9% (8.4-129.9) and in group 3 with peripheral cannulae 63.8% (16.7-113.1) ( Table 3) . There was no significant difference in efficiency among the different types of venous access or in overall efficiency. When the silicone CVC group was broken into three subgroups according to age and size, no significant difference was seen in harvest efficiency between smaller and larger weight patients (Figure 1 symptoms of hypocalcemia (20%), which were treated by oral or intravenous administration of calcium. Nine times (5.5%) a line occlusion in the cell separator was corrected and the collection was continued. During three harvests (1.8%) low blood pressures were observed, and were treated with infusions of a 5% human albumin solution. Two incidents of hypocalcemic tetany (1.2%), two cell separator malfunctions (1.2%) and one displaced program setting problem (0.6%) resulted in discontinuation of the harvest (Table 5) .
Discussion
Pre-existing tunneled silicone CVCs are an alternative access route for PBPC harvesting in children, although the literature has reported a high incidence of occlusion in these catheters, 10 and therefore they are not routinely used for leukapheresis. [11] [12] [13] Our results in children and young adults over 3 years demonstrate that 63.6% of all harvest procedures are feasible with a pre-existing long-term silicone CVC and 15.1% are feasible with peripheral venous cannula used as the draw line. Harvest results, efficiency and changes in peripheral blood and serum values after apheresis are comparable or superior to results reported by other groups using different central venous catheters. [5] [6] [7] [8] [9] The influence of body size or age on harvest efficiency was neg- Table 5 Side-effects ligible, and the need for additional CVC apheresis placements could be reduced to a minimum. When using tunneled silicone rubber catheters for PBPC harvesting, pitfalls can be prevented by appropriate placement of the catheter tip. When the left subclavian vein is chosen as entry site, and the distal opening of the catheter is placed too high, it may adhere to the lateral superior vena cava and disrupt continuity of blood flow. If the catheter tip is placed too low, blood flow may be disturbed by contact with the tricuspid valve or intra-atrial structures. Central venous access by the internal jugular vein with subsequent tunneling of the catheter down along the chest wall often produces a sharp bend at the insertion site, which may cause a collapse of the catheter lumen when negative (draw) pressure is applied. In these cases, peripheral venous cannula with a lumen greater than 1.0 mm may be used as the draw line, and the silicone CVC as return line. 6, 7, 15 When these alternatives fail, it is still possible to install a non-tunneled polyurethane CVC in the subclavian or jugular vein under local or general anesthesia. The large bore double lumen polyurethane CVCs, usually used for dialysis, have stiffer walls and do not easily collapse. In children, additional anesthesia risks, short in situ duration and frequent complications are described: 10 thrombosis of large veins (5%), catheter-related local infections (3%), septicemia (2%), puncture of the carotid artery (2%) and pneumothorax (0.5%) make the use of this catheter problematic (Figure 2) .
Gorlin et al 7 report on results from large volume pediatric aphereses using a Cobe spectra (Cobe Spectra, Denver, CO, USA ) cell collector, and advocate pre-existing silicone CVCs of substantial size (eg at least 10 Fr. Hickman), suggesting that smaller silicone CVCs and peripheral veins are inadequate for apheresis in pediatric patients. This opinion is not confirmed by our experience with the Fenwal CS 3000+ Omnix (Baxter), which showed no significant reduction in PBPC harvest efficiency in small children using 7-9 French silicone CVCs and/or peripheral venous cannulae, when compared with harvest efficiency in older children and young adults using 9-12 French silicone CVCs as the draw line.
Johansson et al 9 compared four types of venous access for PBPC harvesting in adult patients: long-term and shortterm polyurethane CVC, peripheral venous cannulae and conventional CVC. The majority of complications during harvesting occurred with long-term polyurethane CVCs (27%) as compared to 6% in the other groups. Half of the long-term CVCs had to be removed due to complications and 6% of the patients had at least one incident of catheter occlusion during apheresis. They conclude that, in adults, if harvesting is not possible by peripheral venous cannulae, short-term dialysis CVCs are preferable for PBPC collection. In children, short-term dialysis CVCs are used infrequently because of mechanical irritation at the entry site and in the vessel with subsequent infection and thrombosis. For these small patients an additional dialysis catheter poses a serious risk of thrombosis, depending on the size of their large veins. Children old enough to be asked, preferred peripheral venous cannulae to short-term polyurethane CVCs.
Studies in adult patients have been performed to find a multifunctional long-term CVC. Lazarus et al 16 report on their experience with multi-purpose silastic dual-lumen CVCs for both collection and transplantation of PBPC. They were found to be safe, cost-effective and convenient, with complication rates comparable to other CVCs. For 399 apheresis procedures the median time with the catheter in situ was only 63 (7-190) days, which seems short compared to the 177 (36-381) days, reported for Hickman-type silicone CVCs. 17 Although these CVCs are produced in different sizes, implantation in children is not always possible, because the length of the catheter cannot easily be adapted to the patient's size.
Madero et al 8 reported on the use of polyurethane CVCs for stem cell apheresis with the Cobe Spectra cell separator in children. Their harvest results were comparable to ours (mean 6.2 × 10 6 CD34 + cells/kg) and they report a mean CD34 harvest efficacy of 42.78%. Mechanical malfunction (which resolved with thrombolytic therapy) was reported in 3.5% of the harvests, and another 12% needed extreme positional maneuvering due to low flow rates, indicating partial occlusion. Transient hypotensive episodes (3.5%) and citrate toxicity (17.5%) were also reported. This patient group corresponded quite well to our children, yet our results with silicone CVCs using the Fenwal CS 3000+ Omnix for PBPC harvesting resulted in fewer complications and a high CD34 harvest efficiency.
The advantages found when comparing collection data reported in children with our results, together with a lower extracorporal volume and minimized operator variability using the Fenwal CS 3000+ Omnix, show this instrument to be more appropriate for PBPC harvesting in patients with a small body blood volume. Positioning of the catheter tip using the Hickman-type silicone CVC in the superior vena cava and the prevention of sharp bends in the tunneled portion of the catheter requires a skilled CVC team. With correct placement, silicone CVCs may be a better alternative than short-term or long-term dialysis CVCs for PBPC harvesting and provide the possibility of longer in situ placement.
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In conclusion, our results show pre-existing silicone CVCs to be feasible for stem cell harvesting in children and in young adults. To reduce the risks and costs associated with the placement of a second apheresis catheter, preexisting silicone CVCs should be favored for the collection of PBPC.
